Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Niesmann

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Neurophysiology|March 5, 2004
Probability of transmitter release at neocortical synapses at different temperaturesMaxim Volgushev, Igor Kudryashov, Marina Chistiakova, et al.
Lancet (London, England)|December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialRichard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The British Journal of Dermatology|September 12, 2023
Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatmentSascha Gerdes, Petra Staubach, Thomas Dirschka, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Neurophysiology|March 5, 2004
Probability of transmitter release at neocortical synapses at different temperaturesMaxim Volgushev, Igor Kudryashov, Marina Chistiakova, et al.
Lancet (London, England)|December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialRichard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The British Journal of Dermatology|September 12, 2023
Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatmentSascha Gerdes, Petra Staubach, Thomas Dirschka, et al.
Pageof 1